Peregrine Pharmaceuticals (PPHM) is a not yet profitable biotech based in Tustin, California. The company's pipeline consists of first-in-class monoclonal antibodies with a main focus on cancer treatment and imaging. Its three lead programs are in clinical trials for seven separate indications. Peregrine's wholly owned subsidiary, Avid Biosciences, generates enough revenue to partially offset the company's substantial clinical development costs.
Phosphatidylserine-targeting therapy, a new approach to fighting solid tumors
If you can remember your high school biology, you know that cell membranes are mainly composed of a phospholipid bilayer. The water soluble, or hydrophilic, "heads" of newly formed phospholipids face the inside of the cell with their hydrophobic "tails" pointed toward the center of the bilayer. Conversely, the...
Only subscribers can access this article, which is part of the PRO research library covering 3,741 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: